Usual Adult Dose for Myasthenia Gravis

Usual dose: Body weight based dosing

• Less than 50 kg: 420 mg (3 mL) as a subcutaneous infusion once weekly
• 50 kg to less than 100 kg: 560 mg (4 mL) as a subcutaneous infusion once weekly
• 100 kg and above: 840 mg (6 mL) as a subcutaneous infusion once weekly

• Administer the prescribed dose of this medication as a subcutaneous infusion using an infusion pump. The infusion should be set at a rate of up to 20 mL per hour.
• The decision to proceed with additional treatment cycles should be based on clinical assessment. The safety of initiating subsequent cycles within a period shorter than 63 days from the beginning of the previous treatment cycle has not been confirmed.

Renal Dose Adjustments

No adjustment recommended

Liver Dose Adjustments

Data not available

Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS: None

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• This drug should be administered subcutaneously by a healthcare provider using an infusion pump.
• If a scheduled dose is missed, this drug may be administered within 4 days of the scheduled time. Following this, the original dosing schedule should be resumed until the completion of the treatment cycle.

• Store at 36F to 46F (2C to 8C) in the original carton.
• Protect from sunlight until the time of use.
• Do not freeze. Do not shake.
• If necessary, vials can be kept at room temperature, up to 77F (25C), for a maximum period of 30 days while stored in their original carton to shield them from light.
• Once a vial has been stored at room temperature, it should not be returned to the refrigerator.
• The vial should be discarded 30 days after it has been removed from the refrigerator.
• Write the discard date in the designated space on the carton. If the vial is not used within 30 days or if the expiration date has passed before that, discard it.

• Refer to manufacturer product information for detailed information on preparation and administration.

• Patients should be monitored for clinical signs and symptoms of infections.

• Patients should inform their healthcare provider about any history of infections and promptly notify their healthcare provider if they experience any symptoms of an infection.
• Patients should ensure they receive age-appropriate vaccines based on immunization guidelines before starting a new treatment cycle with this drug.
• It is not recommended to receive live or live-attenuated vaccines while undergoing treatment with this drug.
• Patients should be aware that this drug has the potential to cause aseptic meningitis. If they develop symptoms consistent with meningitis, they should contact their healthcare provider.
• Patients should be informed about the signs and symptoms of hypersensitivity reactions. They should immediately contact their healthcare provider if they experience any signs or symptoms of hypersensitivity reactions.